Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572795 | 1.00 | PTGS2 (0.35) | PTGS2ALDH1A1IDO1HDAC6MEN1 | |
| SCHEMBL22031968 | 0.85 | KMT2A (0.45) | PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL29579589 | 0.85 | KDM4E (0.41) | PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL29671158 | 0.85 | KMT2A (0.45) | PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL28574369 | 0.84 | PTGS2 (0.35) | PTGS2ALDH1A1HDAC6HDAC1GRIN3B | |
| Hydrochloric Acid SCHEMBL29671147 | 0.84 | KMT2A (0.45) | PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL29671089 | 0.84 | PTGS2 (0.35) | PTGS2ALDH1A1HDAC6HDAC1GRIN3B | |
| SCHEMBL21979243 | 0.83 | HSD17B10 (0.42) | ALDH1A1MEN1KMT2AGRIN3BGRIN1 | |
| SCHEMBL21979244 | 0.83 | HSD17B10 (0.42) | ALDH1A1MEN1KMT2AGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL30901269 | 0.83 | HDAC8 (0.34) | PTGS2ALDH1A1HDAC6HDAC1GRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | PTGS2 2563/4885ALDH1A1 823/4885IDO1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.